Aldeyra The Cash Flow Conversion Efficiency
Aldeyra The cash flow conversion efficiency. Based on the latest financial reports, Aldeyra The (ALDX) has a cash flow conversion efficiency ratio of -0.121x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.59 Million) by net assets ($37.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aldeyra The (2011–2025)
Cash flow conversion efficiency of Aldeyra The from 2011 to 2025. This chart illustrates how Aldeyra The's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Aldeyra The for real-time trading data and today's change.
Aldeyra The Cash Flow Conversion Ratio Explained
Aldeyra The cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aldeyra The Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aldeyra The ranked by their cash flow conversion efficiency. Also see ALDX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Almondz Global Securities Limited
NSE:ALMONDZ
|
-0.002x |
|
German High Street Properties A/S Class B
CO:GERHSP
|
0.009x |
|
Delticom AG
F:DEX
|
-0.008x |
|
Bedmutha Industries Limited
NSE:BEDMUTHA
|
0.440x |
|
Enogia SAS
PA:ALENO
|
-0.053x |
|
Structural Monitoring Systems Plc
AU:SMN
|
0.187x |
|
Thai Textile Industry Public Company Limited
BK:TTI
|
0.013x |
|
Krungthai Car Rent and Lease Public Company Limited
BK:KCAR
|
0.117x |
Annual Cash Flow Conversion Efficiency for Aldeyra The (2011–2025)
The table below shows the annual cash flow conversion efficiency of Aldeyra The from 2011 to 2025. Review ALDX free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.25 Million | $-33.35 Million | -0.754x | -23.83% |
| 2024-12-31 | $71.00 Million | $-43.21 Million | -0.609x | -140.38% |
| 2023-12-31 | $119.80 Million | $-30.33 Million | -0.253x | +32.50% |
| 2022-12-31 | $151.01 Million | $-56.64 Million | -0.375x | -81.32% |
| 2021-12-31 | $205.74 Million | $-42.56 Million | -0.207x | +67.17% |
| 2020-12-31 | $59.51 Million | $-37.49 Million | -0.630x | +32.66% |
| 2019-12-31 | $48.08 Million | $-44.98 Million | -0.936x | -171.42% |
| 2018-12-31 | $86.62 Million | $-29.86 Million | -0.345x | +28.99% |
| 2017-12-31 | $39.60 Million | $-19.22 Million | -0.485x | +30.62% |
| 2016-12-31 | $21.65 Million | $-15.15 Million | -0.700x | -86.93% |
| 2015-12-31 | $24.88 Million | $-9.31 Million | -0.374x | +50.75% |
| 2014-12-31 | $6.28 Million | $-4.78 Million | -0.760x | +28.08% |
| 2013-12-31 | $1.61 Million | $-1.71 Million | -1.057x | -3516.77% |
| 2012-12-31 | $-25.15 Million | $-778.05K | 0.031x | -96.98% |
| 2011-12-31 | $-2.33 Million | $-2.39 Million | 1.025x | -- |
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary… Read more